 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 2 | 4 | 6 | | 1996 | 5 | 13 | 18 | | 1997 | 6 | 19 | 25 | | 1998 | 3 | 15 | 18 | | 1999 | 9 | 17 | 26 | | 2000 | 6 | 27 | 33 | | 2001 | 10 | 37 | 47 | | 2002 | 13 | 45 | 58 | | 2003 | 11 | 33 | 44 | | 2004 | 9 | 34 | 43 | | 2005 | 9 | 20 | 29 | | 2006 | 7 | 18 | 25 | | 2007 | 13 | 15 | 28 | | 2008 | 10 | 21 | 31 | | 2009 | 10 | 21 | 31 | | 2010 | 9 | 17 | 26 | | 2011 | 11 | 10 | 21 | | 2012 | 12 | 21 | 33 | | 2013 | 5 | 19 | 24 | | 2014 | 10 | 16 | 26 | | 2015 | 7 | 14 | 21 | | 2016 | 7 | 11 | 18 | | 2017 | 5 | 6 | 11 | | 2018 | 7 | 6 | 13 | | 2019 | 1 | 9 | 10 | | 2020 | 6 | 3 | 9 | | 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Gautam D, Pedler MG, Nair DP, Petrash JM. Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor. Biomolecules. 2021 08 04; 11(8).
-
Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P. N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors. Bioorg Med Chem. 2021 07 01; 41:116220.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
-
Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, Cool CD, Sosa-Lozano LA, Baruah D, Hammelev E, Busalacchi A, Rymaszewski A, Woodliff J, Chen S, Bausch-Jurken M, Routes JM. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021 02; 147(2):704-712.e17.
-
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 07 21; 76(3):292-302.
-
Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 06 25; 382(26):2493-2503.
-
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612.
-
Zuhra K, Augsburger F, Majtan T, Szabo C. Cystathionine-ß-Synthase: Molecular Regulation and Pharmacological Inhibition. Biomolecules. 2020 04 30; 10(5).
-
Nashaat S, Henen MA, El-Messery SM, Eisa H. Synthesis, state-of-the-art NMR-binding and molecular modeling study of new benzimidazole core derivatives as Pin1 inhibitors: Targeting breast cancer. Bioorg Med Chem. 2020 06 01; 28(11):115495.
-
Halpern AL, Kohtz PD, White AM, Houk AK, Rehring JF, Hanson L, McCarter MD, Joshi M, Meng X, Fullerton DA, Weyant MJ. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma. Dig Dis Sci. 2021 03; 66(3):784-795.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|